01639nas a2200349   4500000000100000008004100001260001400042653002600056653001600082653001200098653002600110653003000136653001100166653002300177653001200200653002400212653002500236653002500261653000900286653001600295653001300311653001700324653002100341100001400362700001300376700001500389245004900404300000900453490000700462520080600469022001401275       2001                            d  c2001-200210aAnti-Bacterial Agents10aClofazimine10aDapsone10aDrug Hypersensitivity10aDrug Therapy, Combination10aHumans10aLeprostatic Agents10aleprosy10aLeprosy, Borderline10aLeprosy, lepromatous10aLeprosy, Tuberculoid10aMale10aMiddle Aged10aRifampin10aSulfonamides10aThrombocytopenia1 aFlageul B1 aWagner L1 aCottenot F00a[Immuno-allergic accidents with rifamipcin].  a71-80 v123 a<p>We report 2 new cases of immuno-allergic side-effects of rifampicin (RMP), occurred in leprosy patients treated by multidrug therapy. These cases illustrate the various features of this type of complication. In one case, the patient exhibited few days after restarting of RMP (600 mg daily), a typical flu syndrome associated to a thrombopenia. Previously, the patient had received discontinued RMP (300 mg, 3/5 days) that had to be stopped after 11 months for "general malaise" that in fact corresponded to a flu syndrome. The second patient developed a flu syndrome associated with a diffuse eczematous eruption one year after the onset of daily RMP (600 mg). Anti-RMP antibodies were detected only in the first case. The pathogenic mechanisms and the clinico-biologic features are discussed.</p>  a0001-5938